OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW)
<p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therap...
Ausführliche Beschreibung
Autor*in: |
R. V. Savkov [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Russisch |
Erschienen: |
2014 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Onkourologiâ - ABV-press, 2015, 8(2014), 4, Seite 22-26 |
---|---|
Übergeordnetes Werk: |
volume:8 ; year:2014 ; number:4 ; pages:22-26 |
Links: |
---|
Katalog-ID: |
DOAJ041844041 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ041844041 | ||
003 | DE-627 | ||
005 | 20230503001941.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2014 xx |||||o 00| ||rus c | ||
035 | |a (DE-627)DOAJ041844041 | ||
035 | |a (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a rus | ||
100 | 0 | |a R. V. Savkov |e verfasserin |4 aut | |
245 | 1 | 0 | |a OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< | ||
650 | 4 | |a sequential targeted therapy | |
650 | 4 | |a second-line therapy | |
650 | 4 | |a everolimus | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
773 | 0 | 8 | |i In |t Onkourologiâ |d ABV-press, 2015 |g 8(2014), 4, Seite 22-26 |w (DE-627)1736705067 |x 17269776 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2014 |g number:4 |g pages:22-26 |
856 | 4 | 0 | |u https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c |z kostenfrei |
856 | 4 | 0 | |u http://oncourology.abvpress.ru/index.php/oncur/article/view/351 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1726-9776 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1996-1812 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 8 |j 2014 |e 4 |h 22-26 |
author_variant |
r v s rvs |
---|---|
matchkey_str |
article:17269776:2014----::piiainfeodieagtdhrpfreattceaclcrioaacrfeuefefeetryo |
hierarchy_sort_str |
2014 |
publishDate |
2014 |
allfields |
(DE-627)DOAJ041844041 (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c DE-627 ger DE-627 rakwb rus R. V. Savkov verfasserin aut OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< sequential targeted therapy second-line therapy everolimus Medicine R In Onkourologiâ ABV-press, 2015 8(2014), 4, Seite 22-26 (DE-627)1736705067 17269776 nnns volume:8 year:2014 number:4 pages:22-26 https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/351 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 4 22-26 |
spelling |
(DE-627)DOAJ041844041 (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c DE-627 ger DE-627 rakwb rus R. V. Savkov verfasserin aut OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< sequential targeted therapy second-line therapy everolimus Medicine R In Onkourologiâ ABV-press, 2015 8(2014), 4, Seite 22-26 (DE-627)1736705067 17269776 nnns volume:8 year:2014 number:4 pages:22-26 https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/351 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 4 22-26 |
allfields_unstemmed |
(DE-627)DOAJ041844041 (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c DE-627 ger DE-627 rakwb rus R. V. Savkov verfasserin aut OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< sequential targeted therapy second-line therapy everolimus Medicine R In Onkourologiâ ABV-press, 2015 8(2014), 4, Seite 22-26 (DE-627)1736705067 17269776 nnns volume:8 year:2014 number:4 pages:22-26 https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/351 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 4 22-26 |
allfieldsGer |
(DE-627)DOAJ041844041 (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c DE-627 ger DE-627 rakwb rus R. V. Savkov verfasserin aut OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< sequential targeted therapy second-line therapy everolimus Medicine R In Onkourologiâ ABV-press, 2015 8(2014), 4, Seite 22-26 (DE-627)1736705067 17269776 nnns volume:8 year:2014 number:4 pages:22-26 https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/351 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 4 22-26 |
allfieldsSound |
(DE-627)DOAJ041844041 (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c DE-627 ger DE-627 rakwb rus R. V. Savkov verfasserin aut OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< sequential targeted therapy second-line therapy everolimus Medicine R In Onkourologiâ ABV-press, 2015 8(2014), 4, Seite 22-26 (DE-627)1736705067 17269776 nnns volume:8 year:2014 number:4 pages:22-26 https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c kostenfrei http://oncourology.abvpress.ru/index.php/oncur/article/view/351 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2014 4 22-26 |
language |
Russian |
source |
In Onkourologiâ 8(2014), 4, Seite 22-26 volume:8 year:2014 number:4 pages:22-26 |
sourceStr |
In Onkourologiâ 8(2014), 4, Seite 22-26 volume:8 year:2014 number:4 pages:22-26 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
sequential targeted therapy second-line therapy everolimus Medicine R |
isfreeaccess_bool |
true |
container_title |
Onkourologiâ |
authorswithroles_txt_mv |
R. V. Savkov @@aut@@ |
publishDateDaySort_date |
2014-01-01T00:00:00Z |
hierarchy_top_id |
1736705067 |
id |
DOAJ041844041 |
language_de |
russisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ041844041</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503001941.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2014 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ041844041</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">R. V. Savkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sequential targeted therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">second-line therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">everolimus</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Onkourologiâ</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">8(2014), 4, Seite 22-26</subfield><subfield code="w">(DE-627)1736705067</subfield><subfield code="x">17269776</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:22-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://oncourology.abvpress.ru/index.php/oncur/article/view/351</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1726-9776</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1996-1812</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2014</subfield><subfield code="e">4</subfield><subfield code="h">22-26</subfield></datafield></record></collection>
|
author |
R. V. Savkov |
spellingShingle |
R. V. Savkov misc sequential targeted therapy misc second-line therapy misc everolimus misc Medicine misc R OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) |
authorStr |
R. V. Savkov |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1736705067 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
17269776 |
topic_title |
OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) sequential targeted therapy second-line therapy everolimus |
topic |
misc sequential targeted therapy misc second-line therapy misc everolimus misc Medicine misc R |
topic_unstemmed |
misc sequential targeted therapy misc second-line therapy misc everolimus misc Medicine misc R |
topic_browse |
misc sequential targeted therapy misc second-line therapy misc everolimus misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Onkourologiâ |
hierarchy_parent_id |
1736705067 |
hierarchy_top_title |
Onkourologiâ |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1736705067 |
title |
OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) |
ctrlnum |
(DE-627)DOAJ041844041 (DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c |
title_full |
OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) |
author_sort |
R. V. Savkov |
journal |
Onkourologiâ |
journalStr |
Onkourologiâ |
lang_code |
rus |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2014 |
contenttype_str_mv |
txt |
container_start_page |
22 |
author_browse |
R. V. Savkov |
container_volume |
8 |
format_se |
Elektronische Aufsätze |
author-letter |
R. V. Savkov |
title_sort |
optimization of second-line targeted therapy for metastatic renal cell carcinoma cancer after use of vegf receptor – tyrosine kinase inhibitors (literature review) |
title_auth |
OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) |
abstract |
<p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< |
abstractGer |
<p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< |
abstract_unstemmed |
<p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p< |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
4 |
title_short |
OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW) |
url |
https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c http://oncourology.abvpress.ru/index.php/oncur/article/view/351 https://doaj.org/toc/1726-9776 https://doaj.org/toc/1996-1812 |
remote_bool |
true |
ppnlink |
1736705067 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
up_date |
2024-07-03T22:25:19.378Z |
_version_ |
1803598450530451456 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ041844041</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503001941.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2014 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ041844041</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd772e4426f0a4b12be2dcabb94c73b6c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">R. V. Savkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">OPTIMIZATION OF SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA CANCER AFTER USE OF VEGF RECEPTOR – TYROSINE KINASE INHIBITORS (LITERATURE REVIEW)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<<em<Sequential targeted therapy is now the standard of treatment for metastatic renal cell carcinoma (mRCC). A switch into a different mechanism of action of mTOR inhibitor after vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in second-line therapy helps to elude cumulative toxicity and cross-resistance, which may occur in the sequential use of different anti-VEGFR agents through the overlapping mechanisms of action. After VEGFR TKI therapy failure, treatment with the mTOR inhibitor everolimus in second-line therapy is recognized to be effective and safe, substantially increasing progression-free survival, without worsening its quality. Everolimus is recommended as second-line targeted treatment for patients with progressive mRCC after primary VEGFR TKI use. Switching to everolimus is warranted especially in patients who have a poor response to or a high toxicity of first-line antiangiogenic therapy.</em<</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">sequential targeted therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">second-line therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">everolimus</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Onkourologiâ</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">8(2014), 4, Seite 22-26</subfield><subfield code="w">(DE-627)1736705067</subfield><subfield code="x">17269776</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:22-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d772e4426f0a4b12be2dcabb94c73b6c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://oncourology.abvpress.ru/index.php/oncur/article/view/351</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1726-9776</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1996-1812</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2014</subfield><subfield code="e">4</subfield><subfield code="h">22-26</subfield></datafield></record></collection>
|
score |
7.397874 |